- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.03. | Lobe Sciences names Mirza Rahimani as CFO; succeeds Yong Yao | 1 | Seeking Alpha | ||
| 09.03. | Lobe Sciences Ltd.: Lobe Sciences Announces Appointment of Mr. Mirza Rahimani, CPA, CA as Chief Financial Officer | 357 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / March 9, 2026 / Lobe Sciences Ltd. (Lobe) (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is a Canadian public biopharmaceutical company incorporated in British Columbia, with... ► Artikel lesen | |
| 05.03. | Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences | 155 | ACCESS Newswire | VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / March 5, 2026 / Lobe Sciences Ltd. (Lobe) (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is a Canadian public biopharmaceutical company incorporated in British... ► Artikel lesen | |
| 03.02. | Lobe Sciences Ltd (2): Lobe Sciences' Nov. 30 cash at $5.99-million | 1 | Stockwatch | ||
| 03.02. | Lobe Sciences Ltd.: Lobe Sciences Reports First Quarter 2026 Results and Highlights | 318 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / February 3, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases... ► Artikel lesen | |
| 13.01. | Lobe Sciences Ltd (2): Lobe Sciences appoints Karakochuk as director | 1 | Stockwatch | ||
| 13.01. | Lobe Sciences Ltd.: Lobe Sciences Advances Governance and Capital Markets Expertise with Appointment of Mr. Nick Karakochuk to the Board of Directors | 310 | ACCESS Newswire | VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 13, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| 09.01. | Lobe Sciences Ltd (2): Lobe Sciences ends FY 2025 with cash of $5.85-million | 1 | Stockwatch | ||
| LOBE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 08.01. | Lobe Sciences Ltd.: Lobe Sciences Reports FY2025 with a Stronger Balance Sheet and Sharpened Strategy | 228 | ACCESS Newswire | Balance Sheet and Sharpened Strategy VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 8, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical... ► Artikel lesen | |
| 06.01. | Lobe Sciences Ltd (2): Lobe Sciences has cash of $5.85-million at Aug. 31 | 1 | Stockwatch | ||
| 06.01. | Lobe Sciences Ltd.: Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition | 316 | ACCESS Newswire | VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 6, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in... ► Artikel lesen | |
| 24.10.25 | Lobe Sciences Ltd.: Lobe Sciences Completes Debt Settlement to Improve Balance Sheet | 355 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / October 23, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), operates as a pharmaceutical platform that develops novel therapies... ► Artikel lesen | |
| 09.10.25 | Lobe Sciences Ltd (2): Lobe Sciences arranges $137,130 (U.S.) debt settlement | 4 | Stockwatch | ||
| 09.10.25 | Lobe Sciences Ltd.: Lobe Sciences Improves Balance Sheet | 294 | ACCESS Newswire | VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / October 9, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), operates as a pharmaceutical platform that develops... ► Artikel lesen | |
| 16.09.25 | ArcStone US Corp.: Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto | 683 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - September 15, 2025) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe Sciences" or the "Company") a clinical stage biopharmaceutical... ► Artikel lesen | |
| 10.09.25 | Lobe Sciences Ltd. and Cynaptec Pharmaceuticals, Inc. to Present a New Therapeutic Approach for the Treatment of Chronic Cluster Headaches at Clusterbusters 2025 | 508 | ACCESS Newswire | VANCOUVER, B.C. / ACCESS Newswire / September 9, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) a clinical stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| 09.09.25 | Lobe Sciences Ltd.: Lobe Sciences Announces the Appointment of Marco Mastrodonato to its Board of Directors | 491 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / September 8, 2025 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) a clinical stage biopharmaceutical company focused on... ► Artikel lesen | |
| 15.08.25 | Lobe Sciences Ltd.: Lobe Sciences Announces the Closing of the Previously Announced Private Placement | 514 | ACCESS Newswire | NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / August 14, 2025 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company")... ► Artikel lesen | |
| 29.07.25 | Lobe Sciences Ltd. Engages ArcStone Securities for Strategic Capital Markets Advisory | 545 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / July 29, 2025 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company focused on developing therapeutics for rare and underserved diseases... ► Artikel lesen | |
| 29.07.25 | Lobe Sciences Ltd.: Lobe Sciences Announces $341,425 CAD Private Placement for General Corporate Purposes | 528 | ACCESS Newswire | NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / July 29, 2025 / Lobe Sciences Ltd. ("Lobe Sciences"... ► Artikel lesen |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CORE ONE LABS | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,351 | 0,00 % | BioNxt unterzeichnet strategische Vereinbarung zur Vermarktung in Eurasien nach Erteilung des Patents für Cladribin-ODF in Eurasien und Europa | VANCOUVER, BC / ACCESS Newswire /
17. März 2026 / BioNxt Solutions Inc. ("BioNxt" oder das "Unternehmen") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), ein biowissenschaftliches
Innovationsunternehmen... ► Artikel lesen | |
| ATAIBECKLEY | 2,960 | +0,68 % | Milliardenmarkt Depression und PTBS: Wie Emyria und Atai die Psychiatrie-Ökonomie umkrempeln | ||
| SOL GLOBAL INVESTMENTS | 0,052 | +6,12 % | SOL Global Investments Corp.: SOL Global Announces Leadership Transition and Grant of PSUs | Toronto, Ontario--(Newsfile Corp. - February 23, 2026) - SOL Global Investments Corp. (CSE: SOL) (FSE: 9SB) ("SOL Global" or the "Company"), today announced that Mr. Davide Marcotti has resigned... ► Artikel lesen | |
| ENTHEON BIOMEDICAL CORP | 0,042 | 0,00 % | Entheon Biomedical Corp.: Entheon Announces Execution of Business Combination Agreement with Nutravisor | Toronto, Ontario--(Newsfile Corp. - January 19, 2026) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") is pleased to announce that it has entered into... ► Artikel lesen | |
| CYBIN | 4,040 | -1,46 % | Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer | Proven human resources and organizational strategist brings more than two decades of leadership across the pharmaceutical industryAppointment supports Helus Pharma's continued maturation as the company... ► Artikel lesen | |
| REVIVE THERAPEUTICS | 0,020 | -9,09 % | Revive Therapeutics Ltd.: Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases | Patent momentum expands Revive's bucillamine franchise across medical countermeasures, infectious diseases and additional high-value strategic applications TORONTO, ON / ACCESS Newswire / March 11,... ► Artikel lesen | |
| RAPID DOSE THERAPEUTICS | - | - | PTA-News: Rapid Dose Therapeutics Inc.: Rapid Dose Therapeutics sichert sich Patent für die QuickStrip Dünnfilmplattform - für Nikotinprodukte | DJ PTA-News: Rapid Dose Therapeutics Inc.: Rapid Dose Therapeutics (CSE: DOSE) (OTCQB: RDTCF) sichert sich Patent für die QuickStrip Dünnfilmplattform - für Nikotinprodukte
Unternehmensmitteilung... ► Artikel lesen | |
| ERASCA | 14,600 | -4,32 % | Erasca (ERAS) Adds 13%; Soars 310% YTD | ||
| MONTE ROSA THERAPEUTICS | 15,630 | -2,68 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated... ► Artikel lesen | |
| IMMUNOVANT | 22,980 | -2,83 % | Bernstein initiates Immunovant stock coverage with neutral rating | ||
| KYMERA THERAPEUTICS | 77,91 | -2,06 % | Kymera Therapeutics (KYMR) to Present Phase 1b BroADen Trial Data for KT-621 at AAD 2026 | ||
| NURIX THERAPEUTICS | 14,430 | -3,25 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update | First patients dosed in DAYBreak registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that support bexobrutideg's potential best-in-class profile... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 60,92 | -4,72 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results | SAN DIEGO, March 19, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth... ► Artikel lesen | |
| QIAGEN | 34,805 | -1,28 % | Qiagen unter Druck, Zalando auf Erholungskurs: DAX-Ausblick | Der DAX befindet sich weiter auf Talfahrt. In der abgelaufenen Woche büßte das größte deutsche Börsenbarometer rund 144 Punkte ein und schloss -0,61% niedriger mit 23.447 Punkten. Die höchsten Verluste... ► Artikel lesen |
LOBE SCIENCES LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,037 Euro und damit -1,35 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LOBE SCIENCES LTD finden Sie auf Wallstreet Online.